Author： Krauss G. L. Edwards H. B. Lin B.
Publisher： Informa Healthcare
ISSN： 0785-3890
Source： Annals of Medicine, Vol.44, Iss.7, 2012-11, pp. : 674-679
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Lacosamide is a third-generation antiepilepsy drug approved for adjunctive treatment of partial-onset seizures in adults. The pharmacology of lacosamide includes linear kinetics, complete bioavailability, and no major drug interactions. Lacosamide produces slow inactivation of neuronal sodium channels, which differentiates it from other sodium channel modulators, such as carbamazepine and phenytoin. The drug was effective with no major safety problems detected in three large placebo-controlled pivotal trials and has been released in Europe and the US at 200–400 mg/day, divided b.i.d.; an intravenous formulation is approved for temporary conversion from oral therapy. This article reviews the clinical development, pharmacology, and uses of lacosamide for treating partial-onset seizures in adults.
Related content
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, Vol. 51, Iss. 8, 2015-08 ,pp. :
Access to resources
Recommend
Lacosamide for the treatment of partial-onset seizures
By Wong Matthew H Fountain Nathan B
Therapy, Vol. 7, Iss. 5, 2010-09 ,pp. :
Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy
EPILEPSIA, Vol. 56, Iss. 7, 2015-07 ,pp. :